Cargando…

Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption of high-calorie diet and adoption of a sedentary lifestyle, the incidence of NAFLD has surpassed that of viral hepatitis, ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Bao-Fei, Pan, Lan-Fen, Quan, Yi-Fang, Sha, Qian, Zhang, Jing-Zheng, Zhang, Yi-Feng, Zhou, Li-Bing, Qian, Xi-Long, Gu, Xiao-Mei, Li, Feng-Tao, Wang, Ting, Liu, Jia, Zheng, Xian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473922/
https://www.ncbi.nlm.nih.gov/pubmed/37664157
http://dx.doi.org/10.3748/wjg.v29.i31.4744
_version_ 1785100378383056896
author Yan, Bao-Fei
Pan, Lan-Fen
Quan, Yi-Fang
Sha, Qian
Zhang, Jing-Zheng
Zhang, Yi-Feng
Zhou, Li-Bing
Qian, Xi-Long
Gu, Xiao-Mei
Li, Feng-Tao
Wang, Ting
Liu, Jia
Zheng, Xian
author_facet Yan, Bao-Fei
Pan, Lan-Fen
Quan, Yi-Fang
Sha, Qian
Zhang, Jing-Zheng
Zhang, Yi-Feng
Zhou, Li-Bing
Qian, Xi-Long
Gu, Xiao-Mei
Li, Feng-Tao
Wang, Ting
Liu, Jia
Zheng, Xian
author_sort Yan, Bao-Fei
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption of high-calorie diet and adoption of a sedentary lifestyle, the incidence of NAFLD has surpassed that of viral hepatitis, making it the most common cause of chronic liver disease globally. Huangqin decoction (HQD), a Chinese medicinal formulation that has been used clinically for thousands of years, has beneficial outcomes in patients with liver diseases, including NAFLD. However, the role and mechanism of action of HQD in lipid metabolism disorders and insulin resistance in NAFLD remain poorly understood. AIM: To evaluate the ameliorative effects of HQD in NAFLD, with a focus on lipid metabolism and insulin resistance, and to elucidate the underlying mechanism of action. METHODS: High-fat diet-induced NAFLD rats and palmitic acid (PA)-stimulated HepG2 cells were used to investigate the effects of HQD and identify its potential mechanism of action. Phytochemicals in HQD were analyzed by high-performance liquid chromatography (HPLC) to identify the key components. RESULTS: Ten primary chemical components of HQD were identified by HPLC analysis. In vivo, HQD effectively prevented rats from gaining body and liver weight, improved the liver index, ameliorated hepatic histological aberrations, decreased transaminase and lipid profile disorders, and reduced the levels of pro-inflammatory factors and insulin resistance. In vitro studies revealed that HQD effectively alleviated PA-induced lipid accumulation, inflammation, and insulin resistance in HepG2 cells. In-depth investigation revealed that HQD triggers Sirt1/NF-κB pathway-modulated lipogenesis and inflammation, contributing to its beneficial actions, which was further corroborated by the addition of the Sirt1 antagonist EX-527 that compromised the favorable effects of HQD. CONCLUSION: In summary, our study confirmed that HQD mitigates lipid metabolism disorders and insulin resistance in NAFLD by triggering the Sirt1/NF-κB pathway.
format Online
Article
Text
id pubmed-10473922
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-104739222023-09-03 Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway Yan, Bao-Fei Pan, Lan-Fen Quan, Yi-Fang Sha, Qian Zhang, Jing-Zheng Zhang, Yi-Feng Zhou, Li-Bing Qian, Xi-Long Gu, Xiao-Mei Li, Feng-Tao Wang, Ting Liu, Jia Zheng, Xian World J Gastroenterol Basic Study BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption of high-calorie diet and adoption of a sedentary lifestyle, the incidence of NAFLD has surpassed that of viral hepatitis, making it the most common cause of chronic liver disease globally. Huangqin decoction (HQD), a Chinese medicinal formulation that has been used clinically for thousands of years, has beneficial outcomes in patients with liver diseases, including NAFLD. However, the role and mechanism of action of HQD in lipid metabolism disorders and insulin resistance in NAFLD remain poorly understood. AIM: To evaluate the ameliorative effects of HQD in NAFLD, with a focus on lipid metabolism and insulin resistance, and to elucidate the underlying mechanism of action. METHODS: High-fat diet-induced NAFLD rats and palmitic acid (PA)-stimulated HepG2 cells were used to investigate the effects of HQD and identify its potential mechanism of action. Phytochemicals in HQD were analyzed by high-performance liquid chromatography (HPLC) to identify the key components. RESULTS: Ten primary chemical components of HQD were identified by HPLC analysis. In vivo, HQD effectively prevented rats from gaining body and liver weight, improved the liver index, ameliorated hepatic histological aberrations, decreased transaminase and lipid profile disorders, and reduced the levels of pro-inflammatory factors and insulin resistance. In vitro studies revealed that HQD effectively alleviated PA-induced lipid accumulation, inflammation, and insulin resistance in HepG2 cells. In-depth investigation revealed that HQD triggers Sirt1/NF-κB pathway-modulated lipogenesis and inflammation, contributing to its beneficial actions, which was further corroborated by the addition of the Sirt1 antagonist EX-527 that compromised the favorable effects of HQD. CONCLUSION: In summary, our study confirmed that HQD mitigates lipid metabolism disorders and insulin resistance in NAFLD by triggering the Sirt1/NF-κB pathway. Baishideng Publishing Group Inc 2023-08-21 2023-08-21 /pmc/articles/PMC10473922/ /pubmed/37664157 http://dx.doi.org/10.3748/wjg.v29.i31.4744 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Yan, Bao-Fei
Pan, Lan-Fen
Quan, Yi-Fang
Sha, Qian
Zhang, Jing-Zheng
Zhang, Yi-Feng
Zhou, Li-Bing
Qian, Xi-Long
Gu, Xiao-Mei
Li, Feng-Tao
Wang, Ting
Liu, Jia
Zheng, Xian
Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway
title Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway
title_full Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway
title_fullStr Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway
title_full_unstemmed Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway
title_short Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway
title_sort huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering sirt1/nf-κb pathway
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473922/
https://www.ncbi.nlm.nih.gov/pubmed/37664157
http://dx.doi.org/10.3748/wjg.v29.i31.4744
work_keys_str_mv AT yanbaofei huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT panlanfen huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT quanyifang huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT shaqian huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT zhangjingzheng huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT zhangyifeng huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT zhoulibing huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT qianxilong huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT guxiaomei huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT lifengtao huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT wangting huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT liujia huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway
AT zhengxian huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway